Volume | 1,260,217 |
|
|||||
News | - | ||||||
Day High | 7.82 | Low High |
|||||
Day Low | 7.50 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Maravai LifeSciences Holdings Inc | MRVI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
7.61 | 7.50 | 7.82 | 7.70 | 7.58 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
14,645 | 1,260,217 | US$ 7.75 | US$ 9,763,656 | - | 4.52 - 16.62 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:20:01 | formt | 109 | US$ 7.70 | USD |
Maravai LifeSciences Holdings Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.94B | 251.40M | - | 292.23M | -119.03M | -0.47 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Maravai LifeSciences News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRVI Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 7.58 | 8.10 | 7.19 | 7.55 | 1,573,896 | 0.12 | 1.58% |
1 Month | 8.68 | 8.92 | 7.19 | 8.17 | 2,042,829 | -0.98 | -11.29% |
3 Months | 5.30 | 8.92 | 5.045 | 7.53 | 2,818,901 | 2.40 | 45.28% |
6 Months | 6.37 | 8.92 | 4.52 | 6.67 | 2,581,624 | 1.33 | 20.88% |
1 Year | 13.26 | 16.62 | 4.52 | 9.14 | 2,634,117 | -5.56 | -41.93% |
3 Years | 36.66 | 63.55 | 4.52 | 20.75 | 1,963,556 | -28.96 | -79.00% |
5 Years | 31.11 | 63.55 | 4.52 | 21.81 | 1,899,518 | -23.41 | -75.25% |
Maravai LifeSciences Description
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company's segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples. |